<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82101">
  <stage>Registered</stage>
  <submitdate>13/07/2007</submitdate>
  <approvaldate>18/07/2007</approvaldate>
  <actrnumber>ACTRN12607000378426</actrnumber>
  <trial_identification>
    <studytitle>Effects of sitagliptin on gastric emptying in healthy subjects.</studytitle>
    <scientifictitle>Effects of sitagliptin on gastric emptying in healthy subjects.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Gastric emptying</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>sitagliptin 100mg, oral, once daily for 2 days
Study is a crossover design with a washout period of 5 - 14 days (dependent on equipment scheduling)</interventions>
    <comparator>placebo, oral, once daily for 2 days.                                                                                                                                                                                                                                     Placebo tablets will be identical in taste, size and colour to sitagliptin tablets.  Study is a crossover design with a washout period of 5 - 14 days (dependent on equipment scheduling)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Gastric emptying rate</outcome>
      <timepoint>At 15 minute intervals from 0 - 150 minutes, 30 minutes intervals from 150 - 240 minutes.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>GLP-1 levels</outcome>
      <timepoint>At -2 minutes, 15 minute intervals from 0 - 120 minutes, 30 minute intervals from 120 - 240 minutes.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Intragastric Distribution </outcome>
      <timepoint>15 min intervals from 0 - 150 mins, 30 min intervals from 150 - 240 mins</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glycaemia, Insulinaemia and Gastro Intestinal (GI) Hormones</outcome>
      <timepoint>-2 mins, 15 minute intervals from 0 - 120 mins, 30 min intervals from 120 - 240 mins</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Appetite</outcome>
      <timepoint>-2 mins, 15 minute intervals from 0 - 120 mins, 30 min intervals from 120 - 240 mins</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Body Mass Index (BMI) 19-25 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>GI diseaseAlcohol &gt;20g dailyCigarettes &gt;10 per dayPregnant or lactating femalesMedication known to influence GI functionCalculated Creatinine Clearance &lt;60ml/minSubjects exposed to ionising radiation in previous 12 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>random number table using computer program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Subjects, Clinicians and outcome assessors will all be blinded in the study. Code will be broken only for final statistical analysis.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>15/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck Sharpe &amp; Dohme</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This purpose of this study is to evaluate the effect of sitagliptin on gastric emptying, intragastric meal distribution, postprandial glycaemia and insulinaemia in healthy subjects. Glucagon-like peptide-1 (GLP-1) inhibits gastric emptying, thereby slowing the delivery of nutrients, and their absorption, across the small intestine. The rate of entry of carbohydrate into the small intestine is especially important in patients with diabetes. Sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-IV (DPP-IV), the enzyme responsible for the degradation of GLP-1. It is hypothesised that sitagliptin will increase the GLP-1 response to, and thereby slow gastric emptying and diminish the glycaemic response to, a carbohydrate-containing meal.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/01/2007</ethicapprovaldate>
      <hrec>061025</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Karen Jones</name>
      <address>Level 6
Eleanor Harrald Building
Royal Adelaide Hospital
North Terrace 
Adelaide SA 5000</address>
      <phone>08 8222 5394</phone>
      <fax>08 8223 3870</fax>
      <email>karen.jones@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Karen Jones</name>
      <address>Discipline of Medicine
Level 6, Eleanor Harrald Building
Royal Adelaide Hospital
North Terrace  ADELAIDE SA 5000</address>
      <phone>08 8222 5394</phone>
      <fax>08 8223 3870</fax>
      <email>karen.jones@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>